Cell Therapy Manufacturing– tag –
-
University of Queensland Develops Scalable Engineered Extracellular Vesicles for Enhanced Targeted Delivery to Ovarian Cancer
Medical Xpress (University of Queensland) Australia Overview Researchers at the University of Queensland have developed scalable engineered extracellular vesicles (EVs) capable of targeted molecular cargo delivery to ovarian tumors. This... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Kincell Bio Scales Allogeneic Cell Therapy Manufacturing, Bridging Early Clinical to Commercial Supply
Kincell Bio USA Overview Kincell Bio, a specialized CDMO for allogeneic cell therapies, is advancing scalable manufacturing solutions to accelerate product commercialization. The company's expertise focuses on developing efficient proces... -
RoosterBio and Applied StemCell Announce Strategic Partnership for iPSC-Based Bioprocess Solutions
BioSpace USA Overview RoosterBio and Applied StemCell have announced a strategic partnership aimed at developing and commercializing iPSC-based bioprocess solutions. This collaboration combines Applied StemCell's GMP-compatible iPSC tech... -
Catalent and Nanoscope Expand Supply Partnership for Commercialization of Optogenetic Gene Therapy MCO-010 for Retinal Degenerative Diseases
LucidQuest Ventures USA Overview Catalent and Nanoscope Therapeutics have expanded their partnership to support the late-stage development and commercial supply of MCO-010, an optogenetic gene therapy candidate for retinal degenerative d... -
Overcoming Cell Therapy Manufacturing Bottlenecks: Mandating Closed, Reproducible, and Scalable Production Platforms
Frontiers Switzerland Overview As cell therapy products move towards commercialization, their manufacturing processes pose significant challenges regarding critical quality attributes, patient safety, and commercial viability. Addressing... -
Addressing Bottlenecks in Cell and Gene Therapy Manufacturing: Urgent Need for Quality Control and Supply Chain Optimization
Drug Discovery News USA Overview Cell and gene therapy (CGT) manufacturing faces significant bottlenecks, particularly in autologous cell therapies, due to logistical delays and complex quality control challenges. Frequent issues arise w... -
FDA Manufacturing PreCheck Pilot Program Selects 7 Companies Including Cellares to Streamline and Expedite Cell Therapy Manufacturing Processes
RegMedNet UK Overview The FDA has selected seven companies, including Cellares Corp, FUJIFILM Biotechnologies, and Kriya Therapeutics, for its "Manufacturing PreCheck Pilot Program," designed to streamline cell and gene therapy manufactu... -
Cellares’ Cell Shuttle Platform Accepted into FDA’s Inaugural Manufacturing PreCheck Cohort, First and Only Cell Therapy Platform to Receive Designation
BioSpace USA Overview Cellares announced its acceptance into the FDA's inaugural 'Manufacturing PreCheck Pilot Program,' as the sole cell therapy platform among seven companies nationwide. Its automated, end-to-end Cell Shuttle platform ... -
Automated Cell Therapy Manufacturing Lands $1.1 Billion Investment, Poised to Transform Commercialization and Patient Access
Tracxn (Indian Pharma Post経由) India Overview The automated cell therapy manufacturing sector has secured approximately $1.1 billion across 34 funding rounds, reflecting strong investor confidence and paving the way for scalable commerc...
